Results from a big clinical trial show that adding blinatumomab (Blincyto) to the treatment of people with Leuçemia akute limfoblastike (ALL) who are in remission, even if there are no signs of their disease, can help them live longer.
In the study, giving blinatumomab along with chemotherapy made people with cancer that had gone into remission live much longer than those who only got chemotherapy, which is the current standard treatment. Patients in the trial were not only in remission, but there was no sign of their cancer. This is called having minimum residual disease (MRD)-negative ALL.
Rezultatet e provës u shfaqën në takimin vjetor të Shoqatës Amerikane të Hematologjisë (ASH) në New Orleans në dhjetor 2022.
In 2018, the Food and Drug Administration (FDA) cleared blinatumomab to treat people with MRD-positive ALL who were in remission but still showed signs of cancer during follow-up tests. Even though recurrences after remission are always possible, people with MRD-positive ALL have a higher chance of their cancer coming back after their first treatment than those who do not have MRD.
At the ASH meeting, the results were shown for people who did not have MRD after their first medication.
3.5 vjet pas fillimit të terapisë pas faljes, 83% e pacientëve të trajtuar me blinatumomab dhe kimioterapi ishin ende gjallë, ndërsa vetëm 65% e pacientëve të trajtuar vetëm me kimioterapi ishin ende gjallë.
Blinatumomab efektiv edhe për ALL-në MRD-negative
B-cell ALL is the most common type of ALL in both adults and children. It is a type of kanceri i gjakut that spreads quickly and is very dangerous. Chemotherapy is the standard treatment, and it often leads to remission. However, a lot of people get sick again, even if tests done after treatment show no signs of disease.
Immunotherapy drugs have shown some promise as a way to treat cancer after it has gone into remission and lower the risk of it coming back.
Një lloj i Immunotherapy called a bispecific T-cell engager (BiTE) is what blinatumomab is. It sticks to both T cells and cancer cells at the same time. This makes it easy for T cells to find and kill the cancer cell by bringing them closer together. The drug, which is given through an IV, has been shown to be more effective than chemotherapy at treating B-ALL that has come back in children and young adults who have already been treated for it.
Ky test, i cili po drejtohet nga Grupi i Kërkimeve të Kancerit ECOG-ACRIN me ndihmën e NCI, filloi në vitin 2013 për të parë nëse blinatumomab mund të ndihmonte njerëzit që sapo ishin diagnostikuar me ALL të qelizave B.
Edhe pse 488 persona morën pjesë në provë në tërësi, rezultatet e treguara në ASH ishin vetëm për 224 personat që ishin në remision dhe MRD-negativ pas regjimeve të zakonshme fillestare të kimioterapisë. Pacientëve iu dha ose më shumë kimioterapi përveç blinatumomabit ose thjesht kimioterapi. Më pas, të gjithë subjektet morën kimioterapi çdo gjashtë muaj për 2.5 vjet. Disa njerëz gjithashtu morën transplantim të palcës së eshtrave nëse mjeku i tyre mendonte se ishte më e mira.
Jo vetëm që shtimi i blinatumomabit në kimioterapi përmirësoi mbijetesën e përgjithshme, por gjithashtu bëri që pacientët të jetonin më gjatë pa u rikthyer kanceri në krahasim me ata që morën vetëm kimioterapi.
Dr. Litzow said that none of the people who took blinatumomab had any unexpected side effects. Some of the most common side effects of blinatumomab are fever, responses to the infusion, headaches, infections, tremors, and chills.
